Lymphoma Canada,article about lymphoma cancer prognosis,lymphedema causes

Better Quality of Life Seen With Imbruvica for Lymphoma Population

Patients with mantle cell lymphoma (MCL) who were treated with Imbruvica (ibrutinib) had better quality of life (QOL) than those who were gi...

While immune therapies have revolutionized the treatment of melanoma and other cancers, many patients develop resistance to treatment over t...

The Food and Drug Administration has granted an accelerated approval to the PD-L1 inhibitor Bavencio (avelumab) for the treatment of patient...

The FDA has granted an accelerated approval to Tecentriq (atezolizumab) as a frontline treatment for patients with locally advanced or ...

Immunotherapy showed improved survival benefits for stage 3 and 4 melanoma, but it came at a price of greater toxicity, according to a rando...

Previously treated patients with squamous cell carcinoma of the anal canal (SCCA) saw a 24.3 percent overall response rate (ORR) when treate...

Immunotherapy combination regimens may represent the future of urothelial carcinoma treatment, according to Evan Y. Yu, M.D., as it may be a...

Opdivo (nivolumab) showed better long-term survival rates than expected for patients with metastatic non-small cell lung cancer (NSCLC). In ...

When Susan Thornton developed a rash around her waist she wasn’t sure what to make of it. It was a little itchy, but didn’t hurt...

ClearLLab multicolor reagents (T1, T2, B1, B2, M) gained approval from the Food and Drug Administration (FDA) to detect chronic leukemia, ac...